PVLA Stock Analysis: Buy, Sell, or Hold?
PVLA - Palvella Therapeutics, Inc. Common Stock
$146.76
8.50 (6.15%)
▲
5d:
+7.75%
30d:
+40.21%
90d:
+21.91%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When PVLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: PVLA is 8.2% above its trading range ($135.58). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: PVLA is 8.2% above its trading range ($135.58). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: PVLA is currently trading at $146.76, which is considered extended relative to its 30-day fair value range of $105.02 to $135.58.
Technical Outlook: Technically, PVLA is in a uptrend. Immediate support is located at $110.96, while resistance sits at $161.38. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: PVLA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $229.60 (+56.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PVLA is in a uptrend. Immediate support is located at $110.96, while resistance sits at $161.38. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: PVLA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $229.60 (+56.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$105.02 -
$135.58
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range (+8.2% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.1%)
- BULLISH: Trading 56.4% below Wall St target ($229.60)
- CAUTION: Extended 8.2% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$105.02 -
$135.58
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$11.63
(7.9%)
Support & Resistance Levels
Support Level
$110.96
Resistance Level
$161.38
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.52
Wall Street Target
$229.60
(+56.4%)
Share & Embed Analysis
Last updated: July 02, 2026 10:43 PM ET
Data refreshes hourly during market hours. Next update: 11:43 PM
Data refreshes hourly during market hours. Next update: 11:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PVLA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
2
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kathleen Goin
SELL
4302 shares
2026-03-18
Elaine J Heron
BUY
2400 shares
2026-02-27
George M Jenkins
BUY
4000 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
